In preclinical models, treatment with the MFF peptidomimetic displayed anti-cancer activity in patient-derived xenografts, primary breast and non-small cell lung adenocarcinoma organoids, and in glioblastoma neurospheres [118], thus identifying the MFF-VDAC1 complex as an actionable therapeutic target in cancer. The gene discussed is VDAC1; the disease is cancer.